MATRIX PHARMACORP PRIVATE LTD

Overview

MATRIX PHARMACORP PRIVATE LTD is an active pharmaceutical ingredient (API) supplier with 228 active FDA Type II Drug Master Files, covering ABACAVIR SULFATE USP; ABALOPARATIDE; ACYCLOVIR USP; ALENDRONATE SODIUM USP (TRIHYDRATE); ALLOPURINOL USP; ALMOTRIPTAN MALATE USP.

API / Drug Master Files

MATRIX PHARMACORP PRIVATE LTD holds 229 active (229 total) FDA Type II Drug Master Files — identifying it as an active-substance / API supplier. Type II DMFs are filed with the FDA to support the use of an active pharmaceutical ingredient in drug applications.

• SUGAMMADEX SODIUMActive2026-03-30
• AVATROMBOPAG MALEATEActive2025-12-31
• CABOTEGRAVIRActive2025-09-30
• CABOTEGRAVIR SODIUMActive2025-09-29
• SERTRALINE HYDROCHLORIDE USP (FORM-I)Active2025-09-26
• PHENTOLAMINE MESYLATE USP (PROCESS II)Active2025-06-25
• TAPINAROFActive2025-02-05
• ALPRAZOLAM USP (FORM-III)Active2025-01-02
• OLSALAZINE SODIUMActive2023-12-20
• FELBAMATE USP (FEL)Active2023-12-01
• DORAVIRINEActive2023-10-06
• PAROXETINE HYDROCHLORIDE USP (HEMIHYDRATE)Active2023-09-29
• SELEGILINEActive2023-09-27
• BICTEGRAVIR SODIUMActive2022-09-16
• TOFACITINIB CITRATEActive2021-12-15

Showing 15 of 229 Drug Master Files.

FDA compliance signals

No FDA recalls, Warning Letters, or Form 483 observations are linked to MATRIX PHARMACORP PRIVATE LTD in our records. PharmaTek screens the full directory against live FDA enforcement data.